Author:
Rached Layal,Geraud Arthur,Frelaut Maxime,AP Thomas Zoe,Goldschmidt Vincent,Beraud-Chaulet Geoffroy,Nagera-Lazarovici Celine,Danlos Francois-Xavier,Henon Clemence,Parisi Claudia,Gazzah Anas,Bahleda Rastilav,Postel Vinay Sophie,Smolenschi Cristina,Hollebecque Antoine,Michot Jean-Marie,Ribrag Vincent,Loriot Yohann,Champiat Stephane,Ouali Kaissa,Massard Christophe,Ponce Aix Santiago,Bringuier Michael,Baldini Capucine
Reference60 articles.
1. Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17);Amadori;J. Clin. Oncol. J. Am. Soc. Clin. Oncol.,2013
2. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial;Amadori;J. Clin. Oncol.,2016
3. Anon, Loncastuximab Tesirine appendix.pdf. 2023e.
4. Anon, Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA Oncology | JAMA Network. Accessed March 3, 2023d. 〈https://jamanetwork.com/journals/jamaoncology/fullarticle/2650791〉.
5. Anon, Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial - ClinicalKey. Accessed May 24, 2023g. 〈https://www.clinicalkey.fr/#!/content/playContent/1-s2.0-S1470204517303121?returnurl=null&referrer=null〉.